Pharmacy Department, Whitchurch Hospital, Cardiff, UK.
Int J Psychiatry Clin Pract. 2009;13(4):298-302. doi: 10.3109/13651500903046286.
Objective. The aim of this retrospective study was to assess the clinical effectiveness of risperidone long acting injection (RLAI) at 2 years within an acute mental health setting. Method. All patients who received RLAI between July 2002 and December 2004 were identified from pharmacy records, and data collected by retrospective case note review. In order to give an indication that their condition was unresponsive to treatment, patients' drug histories were reviewed to determine whether or not they had previously been treated with clozapine or received two or more failed trials of other antipsychotic medication. Results. Eighty-four patients were included in the study and 56 discontinued at 2 years. The most common reason for treatment discontinuation was lack of effectiveness, accounting for 32 patients, whilst eight patients discontinued due to adverse effects. Patients remaining on treatment spent 67% of the time in an outpatient setting. Conclusion. The proportion of patients remaining on RLAI at 2 years was 33%. Limitations of the naturalistic methodology used in this study hindered any precise determination of which patients were likely to continue RLAI. However, it was apparent that a history of previous treatment failure with at least two antipsychotics was associated with RLAI treatment discontinuation.
本回顾性研究旨在评估利培酮长效注射剂（RLAI）在急性心理健康环境下的 2 年临床疗效。方法：通过回顾病历，从药房记录中确定了所有在 2002 年 7 月至 2004 年 12 月期间接受 RLAI 的患者，并收集了数据。为了表明他们的病情对治疗无反应，回顾了患者的药物史，以确定他们是否曾接受过氯氮平治疗或接受过两次或更多次其他抗精神病药物治疗失败的试验。结果：共有 84 名患者纳入研究，56 名患者在 2 年内停药。最常见的停药原因是疗效不佳，共 32 例，8 例因不良反应停药。接受治疗的患者中有 67%的时间在门诊接受治疗。结论：在 2 年内继续使用 RLAI 的患者比例为 33%。本研究采用的自然主义方法的局限性阻碍了对哪些患者可能继续使用 RLAI 的精确确定。然而，很明显，以前至少两种抗精神病药物治疗失败的病史与 RLAI 治疗的停药有关。
